Betrixaban for Deep Venous Thrombosis Prevention in a Patient with End-Stage Renal Disease on Intermittent Hemodialysis
Victoria M Stevens, Craig J Furnish, Tyree H Kiser · 2026
Read Betrixaban for Deep Venous Thrombosis Prevention in a Patient with End-Stage Renal Disease on Intermittent Hemodialysis by Victoria M Stevens, Craig J Furnish, Tyree H Kiser (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13233004.txt.
Description
Victoria M Stevens, Craig J Furnish, and Tyree H Kiser published a 2026 case report on blood clot prevention in a hospital patient with end-stage kidney disease. The patient received dialysis three times a week and could not take heparin, a standard preventive drug, because of a past reaction called heparin-induced thrombocytopenia. The team chose betrixaban, an oral clot-preventing drug that the kidneys barely clear.
The patient took betrixaban for 15 days, starting with a single 80 milligram dose and then 40 milligrams daily. Blood tests after the second dose showed drug levels inside the expected range, and a day-seven trough level showed no buildup. Seven dialysis sessions took place during admission. No bleeding or clots occurred, suggesting betrixaban may suit similar patients when standard options fail.
Catalog record
| CREATOR | Victoria M Stevens, Craig J Furnish, Tyree H Kiser |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 15 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |